Is Corvus Pharmaceuticals, Inc. (CRVS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 3.9% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.1% / 33% | 3.9% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 1.6% / 33% | 75.4% / 33% | 0.3% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 3.9% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 1.6% / 33% | 75.4% / 33% | 0.3% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -32.6% | |
| Return on Assets (ROA) | -38.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$33M |
| Free Cash Flow | -$33M |
| Total Debt | $937,000 |
| Debt-to-Equity | 1.5 |
| Current Ratio | 6.2 |
| Total Assets | $71M |
Price & Trading
| Last Close | $14.07 |
| 50-Day MA | $17.68 |
| 200-Day MA | $9.16 |
| Avg Volume | 3.5M |
| Beta | 0.8 |
|
52-Week Range
$2.54
| |
About Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Corvus Pharmaceuticals, Inc. (CRVS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Corvus Pharmaceuticals, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Corvus Pharmaceuticals, Inc.'s debt ratio?
Corvus Pharmaceuticals, Inc.'s debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.6%.
What are Corvus Pharmaceuticals, Inc.'s key financial metrics?
Corvus Pharmaceuticals, Inc. has a market capitalization of $1.2B. Return on equity stands at -32.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.